Navigation Links
Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
Date:4/4/2008

ANN ARBOR, Mich., April 4, 2008 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced yesterday that it is responding to a patent infringement complaint by Maquet Cardiovascular LLC. The complaint alleges that Terumo CVS and its parent company, Terumo Corporation, had infringed on two patents related to the sale of the Terumo(R) VirtuoSaph(TM) Endoscopic Vein Harvesting System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

Terumo CVS states that its policy and its practice are not to infringe on the valid intellectual property rights of any company. The VirtuoSaph system is protected by multiple Terumo patents.

"Frankly, we're surprised at this lawsuit as these patents are several years old and our product has been on the market for more than three years with great success," says Mark DiClemente, Vice President, Sales, Terumo Cardiovascular Systems. "Our competitor has only recently entered the vessel harvesting market through an acquisition."

Terumo CVS has sold the VirtuoSaph system in the United States since January 2005. The product is also distributed in Japan and Asia by Terumo Corporation and in Europe by Terumo's European subsidiary.

The VirtuoSaph system is used during coronary artery bypass grafting (CABG), the most common cardiac surgery procedure. During the procedure, the surgeon removes a healthy artery or vein from elsewhere in the body, most often the saphenous vein in the leg, and uses it to route blood around a blockage in a coronary artery. The VirtuoSaph system allows the surgical team to remove the saphenous vein using very small incisions. Endoscopic procedures have been shown to minimize scarring, morbidity and infection associated with traditional longitudinal incisions.

Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery and interventional markets. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. It is one of several subsidiaries of Terumo Corporation of Japan focused exclusively on the cardiac and vascular markets, including Terumo Heart Inc., developer of a ventricular assist device. For more information, visit http://www.terumo-cvs.com.

Terumo Corporation is a premier global medical device company with annual sales in excess of 270,000 (million) yen for the year ending March 31, 2007. Founded in 1921, the company develops, manufactures and distributes world- class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
2. Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology
3. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs ... the Lincoln, Neb. area this year. , The first new location will open ... location will open at 84th and Northern Lights Drive this fall. And the third ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology – Tooth ... to overall dental health, including complications with speech, eating, and overcompensation of mouth due ... replace lost teeth. As the number of tooth replacements increase, it is imperative to ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs ... of e-prescribing as measured in Part D Medicare data. The dataset, called PaPR ... either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: